Open Access · CC BY-NC-ND 4.0
Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies
Molecular Therapy Advances · 2026-11 · 201895
DOI: 10.1016/j.omta.2026.201895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-11. Verfasst von Thijs S. Rietveld und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Rietveld, T. S., Wolf, A. C. M. D., & Hoorn, T. V. D. (2026). Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies. Molecular Therapy Advances, 201895. https://doi.org/10.1016/j.omta.2026.201895
Vancouver
Rietveld TS, Wolf ACMD, Hoorn TVD. Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies. Molecular Therapy Advances. 2026:201895. doi:10.1016/j.omta.2026.201895
BibTeX
@article{Rietveld2026,
author = {Rietveld, Thijs S. and Wolf, A. Charlotte M.T. de and Hoorn, Tineke van den},
title = {Assessing Germline Transmission Risk and First-in-Human Dose Selection for In Vivo Gene Therapies},
journal = {Molecular Therapy Advances},
year = {2026},
pages = {201895},
doi = {10.1016/j.omta.2026.201895}
}
EUVIMED